General Information of Drug (ID: DMW6K80)

Drug Name
Oximidine II Drug Info
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
23645676
CAS Number
CAS 361442-05-9
TTD Drug ID
DMW6K80

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
WY-47766 DM7VCDZ Osteoporosis FB83.0 Discontinued in Phase 2 [2]
SB 242784 DMFXJDL Arterial calcification BD52.Y Preclinical [3]
Salicylihalamide A DMGXVRZ Solid tumour/cancer 2A00-2F9Z Preclinical [1]
FR167356 DMF53Z7 Osteoporosis FB83.0 Preclinical [4]
Lobatamide A DM2GBEW Discovery agent N.A. Investigative [1]
Lobatamide C DMFIDJS Discovery agent N.A. Investigative [1]
Lobatamide D DMG706J Discovery agent N.A. Investigative [1]
Lobatamide B DMD91RI Discovery agent N.A. Investigative [1]
Oximidine I DMG6O0L Discovery agent N.A. Investigative [1]
Lobatamide F DM6BWGQ Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vacuolar-type proton ATPase (v-ATPase) TTTK3BH NOUNIPROTAC Inhibitor [1]

References

1 Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20.
2 A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase. Bone Miner. 1994 Nov;27(2):159-66.
3 SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat. Circ Res. 2002 Sep 20;91(6):547-52.
4 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.